Jentadueto: new combination tablet for type II diabetes

Jentadueto (linagliptin/metformin) is a new fixed-dose combination tablet for patients with type II diabetes inadequately controlled by diet and exercise.

Jentadueto is a new single-tablet treatment option for type II diabetes, taken twice daily.
Jentadueto is a new single-tablet treatment option for type II diabetes, taken twice daily.

It is licensed for use when metformin alone is inadequate; in patients who are currently receiving the combination as separate tablets; or with a sulfonylurea when a sulfonylurea plus metformin is inadequate.

PHARMACOLOGY

Jentadueto provides a fixed dose of two antidiabetic agents with complementary mechanisms of action: linagliptin, a dipeptidyl peptidase 4 inhibitor and metformin, a member of the biguanide class.1

CLINICAL STUDIES

A randomised, double-blind 24-week phase III study assessed the efficacy and safety of linagliptin plus metformin in 791 patients with type II diabetes. Patients received either a combination of linagliptin and metformin, metformin alone, linagliptin alone or placebo. Linagliptin was given at 2.5mg twice daily in combination treatment and at 5mg once daily in monotherapy. Metformin was given at either 500mg or 1g twice daily for both combination treatment and monotherapy.2

At maximum dose (linagliptin 2.5mg/metformin 1g twice daily), the combination provided a placebo-corrected mean reduction in glycosylated haemoglobin (HbA1c), the primary endpoint, of up to  –1.7% (95% CI –2.0 to –1.4, p<0.0001). Corresponding reductions were –1.3% for linagliptin 2.5mg/metformin 500mg, –1.2% for metformin 1g, 0.8% for metformin 500mg and –0.6% for linagliptin. Both doses of the combination were superior to metformin or linagliptin monotherapy (p<0.0001 for all comparisons).2

The most frequently reported adverse reactions with linagliptin plus metformin were diarrhoea and nasopharyngitis. Rates of hypoglycaemia for the combination (1.7%) were similar to those for metformin alone (2.4%).2

References:

1.    Jentadueto Summary of Product Characteristics, July 2012.
2.    Haak T et al. Diabetes Obes Metab 2012; 14: 565-74.

View Jentadueto drug record
 
Further information: Boehringer Ingelheim

Follow MIMS on Twitter


Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

News in brief - April 2014 (updated)

News in brief - April 2014 (updated)

Other new launches, licence changes and updates relevant...

Komboglyze: new hypoglycaemic combination

Komboglyze: new hypoglycaemic combination

Bristol-Myers Squibb and AstraZeneca have launched...

Pancreatitis risk with DPP4 inhibitors

Pancreatitis risk with DPP4 inhibitors

Acute pancreatitis is now listed as a possible adverse...

Trajenta launched for type II diabetes

Trajenta launched for type II diabetes

Trajenta (linagliptin) is a new once daily DPP4 inhibitor...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases